SCHEMBL17834619

SCHEMBL17834619

C[C@@H](NC(=O)[C@H](Cc1ccc(-c2ncc(-c3ccc(-c4ccc(OC(F)(F)F)cc4)cc3F)cn2)cc1)NC(=O)c1ccc(C(C)(C)C)s1)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 1/20 0.39
GPR132 Q9UNW8 1/20 0.38
MMP12 P39900 2/20 0.37
USP30 Q70CQ3 1/20 0.36
ITGB1 P05556 1/20 0.36
ITGA4 P13612 1/20 0.36
ITGB7 P26010 1/20 0.36
KIFC1 Q9BW19 4/20 0.36
ALOX5AP P20292 3/20 0.35
FEN1 P39748 3/20 0.35
ABL1 P00519 1/20 0.35
GCGR P47871 1/20 0.35
KIF11 P52732 1/20 0.34
ACE P12821 1/20 0.34
MME P08473 1/20 0.34
ANPEP P15144 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17834439 0.95 MMP12 (0.37) KLKB1GPR132MMP12USP30ITGB1
SCHEMBL17834514 0.93 GPR132 (0.44) KLKB1GPR132MMP12USP30ITGB1
SCHEMBL16306238 0.92 FFAR4 (0.40) KLKB1GPR132MMP12USP30ITGB1
SCHEMBL17834625 0.92 KIFC1 (0.37) KIFC1ALOX5APFEN1MMEANPEP
SCHEMBL17834504 0.92 MME (0.41) KIFC1ALOX5APFEN1MMEANPEP
SCHEMBL19485720 0.92 KLKB1 (0.42) KLKB1GPR132MMP12USP30ITGB1
SCHEMBL17834843 0.91 KIFC1 (0.34) KLKB1ITGB1ITGA4ITGB7KIFC1
SCHEMBL17834840 0.91 ALOX5AP (0.42) KIFC1ALOX5APFEN1
SCHEMBL17834620 0.91 KIFC1 (0.37) KIFC1ALOX5APFEN1MMEANPEP
SCHEMBL17834494 0.90 KIFC1 (0.41) KIFC1ALOX5APFEN1MMEANPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3230276-B1 GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-09-02 EP disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 US disclosed
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2018-01-25 US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 US disclosed
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-08-11 US disclosed
WO-2016094729-A1 GLP-1 RECEPTOR MODULATORS CELGENE INTERNATIONAL II SARL (CH) 2016-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R KLKB1 2855/4885GPR132 178/4885MMP12 4516/4885
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R KLKB1 2855/4885GPR132 178/4885MMP12 4516/4885
US-10034886-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR KLKB1 2865/4885GPR132 228/4885MMP12 4447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.